The new strategy makes a number of proposals that considerably widen the scope of patients' and consumers' contribution to the EMA. This includes consultation during benefit-risk evaluation of medicines, participation as observers in meetings of the Pharmacovigilance Working Party and contribution to the Agency's safety communication. The new strategy also foresees financial support to facilitate the participation of patients' and consumers' representatives.

The document endorsed by the EMA's Management Board is available here.

For more information on the patients' and consumers' organisations involved in the EMA's activities, please click here.